Patent

Natco vs Roche (Doha License): First Day


I’ve been given to understand that Natco’s counsel presented arguments before the patent office today. However, it appears that most of the arguments were centered around the interlocutory application filed by Natco, opposing the move by the patent office to hear Roche/Pfizer. Tomorrow, the patent office will hear arguments in this regard from counsels representing Pfizer/Roche. It is only after they decide on this interlocutory application (i.e. that parties cannot be heard under section 92A) that the matter will be…


Read More »
Patent

SpicyIP Tidbit: Sun challengesJ&J


Sun Pharma has as of February 28th, 2008 decided to file a post grant opposition with the Mumbai patent office against a product patent extension granted to Johnson & Johnson’s Risperdal, used to treat psychological disorders and schizophrenia. The patent, granted to Janssen Pharmaceutica, a group company of Johnson & Johnson, on July 20, 2007, with patent number 208191 relates to sustained-release particles of risperidone.Sun Pharma has been marketing a generic version of this drug for the last few years…


Read More »

SpicyIP Tidbits: Interpol to Step in to Protect IPR


Tightening the noose on counterfeiting of goods for protection of IPR, a Database on International Intellectual property (DIIP) was launched at a Confederation of Indian Industry (CII) forum in Mumbai, as part of a joint initiative by the Interpol and the US Chamber of Commerce. Laying emphasis on the importance of protection of IPR in countries like India and China, Ron Noble, secretary general of Interpol and David Chavern, executive vice president and chief operating officer of the U S…


Read More »
Patent

SpicyIP Tidbits: Pharma MNCs struggle in India


Three years after India’s patent law refurbishing exercise, the verdict is out: MNCs are still struggling to carve a sizeable pie of the Indian market share, while domestic pharma majors continue to rule the roost. A report by Noemie Bisserbe of the ET gives several probable reasons for Pfizer, Novartis and Merck losing market capitalisation over the past three years, including poor pricing strategies and fewer global product launches. Elsewhere, at an ET summit on the Indian pharma industry, Dr…


Read More »
Patent

SpicyIP Tidbits: It’s a Case of Purple Heartburn


Here’s the story so far. AstraZeneca, the Anglo-Swedish manufacturer of prescription drugs had a basic patent on Prilosec (Omeprazole), a drug used to treat gastroesophageal reflux disease (acid reflux) and heartburn. Gastroesophageal reflux disease is the name given to erosions in the oesophagus on account of churning of pepsin in the stomach over a period of time which chips away at the delicate lining of oesophagus. This patent was supposed to expire in April 2001. However, the company came up…


Read More »

SpicyIP Tidbits: Basmati ‘stirs’ up new protests.


Just when India’s initiative to protect products was finally beginning to be appreciated by SpicyIP, farmers in Karnataka have begun protesting the recent move to grant the geographical indication to the rice grown in Punjab, Haryana, UP and Uttarakhand alone. Claiming that this would adversely affect the margin on profits earned by the variety of Basmati grown by them, the farmers have now started protesting, in the hope that they will be included as a part of the GI. The…


Read More »

Free IP Database: The WIPO Magazine!


The World Intellectual Property Organisation’s magazine endeavours to inform readers about WIPO-led activities, and to showcase intellectual property, creativity and innovation at work across the world, this issue of the WIPO Magazine covers a wide range of topics like from climate change to a public forum at the WIPO for LDCs. The WIPO Magazine is currently available free of charge. This can be availed by readers- both online and in print in three languages (English, French, Spanish). The launch of…


Read More »
Uncategorized

Spicy Tidbit: Injunction granted in HCV TRI-DOT case


J Mitra’s company dealing with HCV-TRIDOT( a device for the detection of the Hepatitis C within 10-15 days) has been granted an injunction in its favour preventing Span Diagnostics from making or selling any diagnostic test which might infringe their patent. “The defendant (Span Diagnostics) and its agents are restrained from manufacturing, selling, offering for sale or in any manner dealing with the impugned product Signal HCV or any other product violative of the plaintiff’s (J Mitra’s) patent,” Justice Sanjay…


Read More »

The Tale of the Two Patents: SpicyIP in the news.


Our readers are most likely to remember the recent patent blooper with the issue of the same patent to different inventors. This was preceded by SpicyIP’s appeal to the Prime Minister to create a database of sorts to prevent exactly these sort of incidents. As a followup to the previous post by Mr. Basheer, CH Unnikrishnan from Livemint not only reports this patent issue, but acknowledging SpicyIP’s role in the same- has closely followed the recent developments in the story–…


Read More »
Patent

India’s First Doha Case: Has Nepal Issued a Notitication?


Pursuant to our posts on the Natco’s application for a Doha Style Compulsory license to export two anti-cancer drugs patented by Roche/Pfizer, there have been some articles on this theme in the mainstream media. We bring you two of them in this post. For our earlier posts, see here (in particular see the exchange with Tahir Amin in the “comments” section of the blog post), and here. Tatum Anderson wrote a piece in IP Watch and Jonathan Allen reports on…


Read More »